11:03 AM
Nov 27, 2017
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Liver cancer

Cell culture studies suggest inhibiting PDE3A, FYB1, BICC1 or PURPL could help treat liver cancer. In two human liver cancer cell lines, shRNA targeting PDE3A, FYB1, BICC1...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >